Evidence map›Paper›PMID 30375574›Full record

ArticleArchives of rheumatology2016

Relationship Between Leptin and Neopterin Levels and Disease Activation Parameters in Patients With Rheumatoid Arthritis.

Arif Gülkesen, Gürkan Akgöl, Türkan Tuncer, Gül Ayden Kal, Selda Telo, Ahmet Kürşad Poyraz, Arzu Kaya

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of rheumatology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Leptin: an unappreciated key player in SLE.Clinical rheumatology · 2020
    Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Arif GülkesenDepartment of Physical Medicine and Rehabilitation, Medical Faculty of Fırat University, Elazığ, Turkey.
Gürkan AkgölDepartment of Physical Medicine and Rehabilitation, Medical Faculty of Fırat University, Elazığ, Turkey.
Türkan TuncerDepartment of Physical Medicine and Rehabilitation, Siirt State Hospital, Siirt, Turkey.
Gül Ayden KalDepartment of Physical Medicine and Rehabilitation, Elazığ Training and Research Hospital, Elazığ, Turkey.
Selda TeloDepartment of Biochemistry and Clinical Biochemistry, Medical Faculty of Fırat University, Elazığ, Turkey.
Ahmet Kürşad PoyrazDepartment of Radiology, Medical Faculty of Fırat University, Elazığ, Turkey.
Arzu KayaDepartment of Physical Medicine and Rehabilitation, Medical Faculty of Fırat University, Elazığ, Turkey.
Fırat University · TRAnkara University · TRElazığ Eğitim ve Araştırma Hastanesi · TRIstanbul University · TRSiirt Üniversitesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesThis study aims to determine serum leptin and neopterin levels in patients with rheumatoid arthritis (RA) and investigate the relationship between clinical and laboratory parameters of disease activity and radiographic progression. PATIENTS AND

methodsThe study included 33 RA patients (9 males, 24 females; mean age 52.5±12.3 years; range 29 to 75 years) and age- and sex-matched 24 healthy controls (11 males, 13 females, mean age 42.5±14.8; range 18 to 75). RA patients were divided into three groups based on Disease Activity Scores in 28 joints (DAS28) as low disease activity, moderate disease activity, and high disease activity groups. Of the patients, 13 (39.4%) had low disease activity (DAS28=2.6-3.2), 12 (36.4%) had moderate disease activity (DAS28=3.2-5.1), and eight (24.2%) had high disease activity (DAS28≥5.1).

resultsMean serum leptin and neopterin levels in the RA group were 23.98±18.88 ng/mL and 1.88±1.84 nmol/L, respectively. Mean serum leptin and neopterin levels in the control group were 19.40±13:42 ng/mL and 1.13±0.55 nmol/L, respectively. There was no statistically significant difference in the levels of serum leptin (p=0.674) and neopterin (p=0.078) between RA patients and control group. Serum leptin (p=0.574) and neopterin (p=0.921) levels in RA patients and control group showed no correlation with body mass index levels. Besides, there was no correlation between age and plasma leptin and neopterin levels and rheumatoid factor positivity, anti-cyclic citrullinated peptide antibodies, disease duration, erythrocyte sedimentation rate, and C-reactive protein levels in RA group. In RA patients, there was no correlation between serum leptin and neopterin levels and clinical and laboratory parameters indicating the disease activity. In RA patients, there was also no correlation between radiographic joint damage and serum leptin and neopterin levels. A positive correlation was shown in RA patients between disease duration and modified Larsen score (p=0.01).

conclusionIn our study, no correlation was detected between serum leptin and neopterin levels and disease activity parameters in RA patients. Therefore, leptin and neopterin levels may not be considered as beneficial inflammation parameters to be used in the diagnosis of RA and disease activation tracking.

Indexed as

Disease activityleptinneopterinrheumatoid arthritis

Identifiers

PMID30375574
PMCPMC6190973
OpenAlexW2342964420

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.